×
About 2,478 results

ALLMedicine™ CAR T-cell Therapy Center

Research & Reviews  851 results

Cardiovascular Toxicities of CAR T-cell Therapy.
https://doi.org/10.1007/s11912-021-01068-0
Current Oncology Reports; Patel NP, Doukas PG et. al.

May 3rd, 2021 - This review provides a contemporary overview of current studies outlining the incidence and characteristics of CAR T-cell cardiotoxicity in an effort to identify future directions for research and potential opportunities for prevention and interve...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

CAR T-cell therapy in multiple myeloma: more room for improvement.
https://doi.org/10.1038/s41408-021-00469-5 10.1007/s40268-019-0269-9 10.1016/S1470-2045(14)71125-8 10.3389/fimmu.2019.01613 10.1016/j.mayocp.2017.01.003 10.1038/s41375-018-0196-8 10.1016/j.clml.2015.07.641 10.1038/leu.2013.247 10.1146/annurev-immunol-042718-041407 10.1053/j.gastro.2012.06.037 10.1126/scitranslmed.3002842 10.1089/hum.2017.254 10.1007/s11899-017-0373-2 10.1097/HS9.0000000000000188 10.1172/JCI85309 10.1016/S0140-6736(20)31366-0 10.1073/pnas.90.2.720 10.1038/nm827 10.1097/CJI.0b013e318194a6e8 10.1038/mto.2016.11 10.2217/imt.14.86 10.3389/fimmu.2018.02486 10.1038/nm.3838 10.1038/mt.2009.83 10.1084/jem.188.4.619 10.1111/imr.12125 10.1158/0008-5472.CAN-11-0103 10.1158/1078-0432.CCR-12-2422 10.1016/j.ccell.2017.02.002 10.1089/hum.2018.001 10.1182/blood-2004-11-4512 10.1182/blood-2016-01-691162 10.3324/haematol.2016.150896 10.1182/blood-2016-04-711903 10.1200/JCO.2018.77.8084 10.1056/NEJMoa1817226 10.1182/blood-2018-99-116953 10.1200/JCO.2020.38.15_suppl.8525 10.1056/NEJMoa2024850 10.1182/blood-2020-142426 10.1182/blood-2019-121731 10.1182/blood-2020-136307 10.1182/blood-2020-140243 10.1038/s41375-020-0734-z 10.1182/blood-2020-136748 10.1186/s13045-020-01001-1 10.1007/s12254-020-00571-7 10.1182/blood-2020-139040 10.1182/blood-2019-129088 10.1186/s12943-019-1092-1 10.1111/j.1365-2141.2012.09241.x 10.1182/blood-2020-137786 10.1056/NEJMoa1805762 10.1056/NEJMoa1505654 10.1182/blood-2017-04-778423 10.1038/s41467-020-16160-5 10.1016/S2352-3026(20)30081-8 10.1016/S0140-6736(15)01120-4 10.1182/blood-2016-09-740787 10.1080/10428194.2017.1393668 10.3324/haematol.2015.137620 10.1182/blood-2019-130340 10.1182/blood-2017-05-781351 10.1182/bloodadvances.2019000703 10.1038/s41375-018-0242-6 10.1182/blood-2020-136704 10.1172/JCI126397 10.3390/cancers12092523 10.1002/cam4.2257 10.1016/j.cellimm.2019.103964 10.1182/blood-2020-141062 10.1126/scitranslmed.aaf8621 10.1182/blood.V126.23.100.100 10.1182/blood-2018-99-113548 10.1182/blood.V128.22.2127.2127 10.1182/blood-2019-129562 10.1182/blood.2019000050 10.1182/blood-2020-142572 10.1182/blood-2019-129582 10.1182/blood-2016-03-703439 10.1182/blood-2019-130654 10.1371/journal.pone.0247701 10.1158/1535-7163.MCT-18-1146 10.1158/1078-0432.CCR-17-0344 10.1038/s41375-020-0745-9 10.1172/JCI86437 10.1097/CJI.0000000000000061 10.1182/blood-2020-139009 10.1038/s41573-019-0051-2 10.1182/blood-2018-99-116443 10.1182/blood-2020-139516 10.1182/blood-2020-141477 10.1016/j.ebiom.2020.102975 10.1016/j.canlet.2019.11.033 10.1182/blood-2020-142750 10.1016/j.ymthe.2020.11.028
Blood Cancer Journal; Teoh PJ, Chng WJ

Apr 30th, 2021 - The emergence of various novel therapies over the last decade has changed the therapeutic landscape for multiple myeloma. While the clinical outcomes have improved significantly, the disease remains incurable, typically in patients with relapsed a...

Approvals Expand Multiple Myeloma Treatment Options.
https://doi.org/10.1158/2159-8290.CD-NB2021-0338
Cancer Discovery;

Apr 28th, 2021 - Two recent FDA approvals broaden the treatment landscape for multiple myeloma. The approvals include the first CAR T-cell therapy for the disease, idecabtagene vicleucel, and a monoclonal antibody targeting CD38, isatuximab-irfc.

What is CAR T-cell therapy?
https://doi.org/10.1136/dtb.2020.000040
Drug and Therapeutics Bulletin; Kew K

Apr 28th, 2021 - The emergence of targeted and precision therapies has increased treatment options for people living with cancer. Of particular note is the development and approval of chimeric antigen receptor (CAR) T-cell therapies that involve the use of a patie...

see more →

Guidelines  23 results

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
https://www.healio.com/news/hematology-oncology/20200706/dual-target-car-tcell-therapy-effective-durable-less-toxic-in-lymphoma

Jul 5th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-...

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

CAR T-cell therapy could ‘revolutionize’ treatment of advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{808d4883-a0e1-4574-b61d-ec5ce62aa752}/car-t-cell-therapy-could-revolutionize-treatment-of-advanced-multiple-myeloma

May 29th, 2020 - JNJ-4528, a chimeric antigen receptor T-cell therapy, induced early, deep and durable responses among patients with relapsed or refractory multiple myeloma, according to study results presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
https://www.targetedonc.com/view/car-t-cell-therapy-with-axi-cel-holds-promise-in-r-r-indolent-nhl

May 29th, 2020 - Patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor (CAR) T-cell therapy of axicabtagene ciloleucel (axi-cel; Yescarta) had high rates of complete response (CR) and demonstrated th...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  1,215 results

Cardiovascular Toxicities of CAR T-cell Therapy.
https://doi.org/10.1007/s11912-021-01068-0
Current Oncology Reports; Patel NP, Doukas PG et. al.

May 3rd, 2021 - This review provides a contemporary overview of current studies outlining the incidence and characteristics of CAR T-cell cardiotoxicity in an effort to identify future directions for research and potential opportunities for prevention and interve...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

CAR T-cell therapy in multiple myeloma: more room for improvement.
https://doi.org/10.1038/s41408-021-00469-5 10.1007/s40268-019-0269-9 10.1016/S1470-2045(14)71125-8 10.3389/fimmu.2019.01613 10.1016/j.mayocp.2017.01.003 10.1038/s41375-018-0196-8 10.1016/j.clml.2015.07.641 10.1038/leu.2013.247 10.1146/annurev-immunol-042718-041407 10.1053/j.gastro.2012.06.037 10.1126/scitranslmed.3002842 10.1089/hum.2017.254 10.1007/s11899-017-0373-2 10.1097/HS9.0000000000000188 10.1172/JCI85309 10.1016/S0140-6736(20)31366-0 10.1073/pnas.90.2.720 10.1038/nm827 10.1097/CJI.0b013e318194a6e8 10.1038/mto.2016.11 10.2217/imt.14.86 10.3389/fimmu.2018.02486 10.1038/nm.3838 10.1038/mt.2009.83 10.1084/jem.188.4.619 10.1111/imr.12125 10.1158/0008-5472.CAN-11-0103 10.1158/1078-0432.CCR-12-2422 10.1016/j.ccell.2017.02.002 10.1089/hum.2018.001 10.1182/blood-2004-11-4512 10.1182/blood-2016-01-691162 10.3324/haematol.2016.150896 10.1182/blood-2016-04-711903 10.1200/JCO.2018.77.8084 10.1056/NEJMoa1817226 10.1182/blood-2018-99-116953 10.1200/JCO.2020.38.15_suppl.8525 10.1056/NEJMoa2024850 10.1182/blood-2020-142426 10.1182/blood-2019-121731 10.1182/blood-2020-136307 10.1182/blood-2020-140243 10.1038/s41375-020-0734-z 10.1182/blood-2020-136748 10.1186/s13045-020-01001-1 10.1007/s12254-020-00571-7 10.1182/blood-2020-139040 10.1182/blood-2019-129088 10.1186/s12943-019-1092-1 10.1111/j.1365-2141.2012.09241.x 10.1182/blood-2020-137786 10.1056/NEJMoa1805762 10.1056/NEJMoa1505654 10.1182/blood-2017-04-778423 10.1038/s41467-020-16160-5 10.1016/S2352-3026(20)30081-8 10.1016/S0140-6736(15)01120-4 10.1182/blood-2016-09-740787 10.1080/10428194.2017.1393668 10.3324/haematol.2015.137620 10.1182/blood-2019-130340 10.1182/blood-2017-05-781351 10.1182/bloodadvances.2019000703 10.1038/s41375-018-0242-6 10.1182/blood-2020-136704 10.1172/JCI126397 10.3390/cancers12092523 10.1002/cam4.2257 10.1016/j.cellimm.2019.103964 10.1182/blood-2020-141062 10.1126/scitranslmed.aaf8621 10.1182/blood.V126.23.100.100 10.1182/blood-2018-99-113548 10.1182/blood.V128.22.2127.2127 10.1182/blood-2019-129562 10.1182/blood.2019000050 10.1182/blood-2020-142572 10.1182/blood-2019-129582 10.1182/blood-2016-03-703439 10.1182/blood-2019-130654 10.1371/journal.pone.0247701 10.1158/1535-7163.MCT-18-1146 10.1158/1078-0432.CCR-17-0344 10.1038/s41375-020-0745-9 10.1172/JCI86437 10.1097/CJI.0000000000000061 10.1182/blood-2020-139009 10.1038/s41573-019-0051-2 10.1182/blood-2018-99-116443 10.1182/blood-2020-139516 10.1182/blood-2020-141477 10.1016/j.ebiom.2020.102975 10.1016/j.canlet.2019.11.033 10.1182/blood-2020-142750 10.1016/j.ymthe.2020.11.028
Blood Cancer Journal; Teoh PJ, Chng WJ

Apr 30th, 2021 - The emergence of various novel therapies over the last decade has changed the therapeutic landscape for multiple myeloma. While the clinical outcomes have improved significantly, the disease remains incurable, typically in patients with relapsed a...

Palliative Care 'Should Be Given Early in CAR T-Cell Therapy'
https://www.medscape.com/viewarticle/950268

Apr 29th, 2021 - Sophie was at university, in the second year of her undergraduate degree in biology, when she was diagnosed with acute lymphoblastic leukaemia (ALL). It was 2018 and she had just turned 20. She started treatment straight away, and "there was no ti...

Approvals Expand Multiple Myeloma Treatment Options.
https://doi.org/10.1158/2159-8290.CD-NB2021-0338
Cancer Discovery;

Apr 28th, 2021 - Two recent FDA approvals broaden the treatment landscape for multiple myeloma. The approvals include the first CAR T-cell therapy for the disease, idecabtagene vicleucel, and a monoclonal antibody targeting CD38, isatuximab-irfc.

see more →

News  387 results

Palliative Care 'Should Be Given Early in CAR T-Cell Therapy'
https://www.medscape.com/viewarticle/950268

Apr 29th, 2021 - Sophie was at university, in the second year of her undergraduate degree in biology, when she was diagnosed with acute lymphoblastic leukaemia (ALL). It was 2018 and she had just turned 20. She started treatment straight away, and "there was no ti...

Made-to-Order TILs Effective Against Metastatic Melanoma
https://www.medscape.com/viewarticle/949329

Apr 14th, 2021 - In just over one third of patients with metastatic melanoma who had experienced disease progression while receiving multiple prior lines of therapy, including immunotherapy and targeted agents, objective clinical responses occurred with a customiz...

First CAR T-Cell Therapy for Multiple Myeloma: Abecma
https://www.medscape.com/viewarticle/948248

Mar 28th, 2021 - Chimeric antigen receptor (CAR) T-cell therapy, described as a "living drug," is now available for patients with relapsed/refractory multiple myeloma who have been treated with four or more prior lines of therapy. The US Food and Drug Administrati...

First CAR T-cell Therapy for Mantle Cell Lymphoma Fills Unmet Need
https://www.medscape.com/viewarticle/943428

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

see more →